Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials

British Journal of Cancer

Volumn 101, Issue 1, 2009, Pages 12-18

  Shiroiwa, T ^a   Fukuda, T ^a   Tsutani, K ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Capecitabine; Colorectal cancer; Cost effectiveness analysis; FOLFOX

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FOLIC ACID; PLATINUM COMPLEX;

ADULT; AGE DISTRIBUTION; AMINO ACID SEQUENCE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE COURSE; DRUG COST; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE UTILIZATION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NATIONAL HEALTH SERVICE; NAUSEA AND VOMITING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOM SAMPLE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEX DIFFERENCE; SEX RATIO; STOMATITIS; TREATMENT OUTCOME; UNITED KINGDOM; COLORECTAL TUMOR; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; ECONOMICS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; QUALITY OF LIFE; RETROSPECTIVE STUDY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; FOLIC ACID; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 67649859435     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605114     Document Type: Article

References (31)

1. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky RL (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/ leucovorin. Ann Oncol 13: 566-575
2. Center for Cancer Control and Information Services (2007) National Cancer Center, Japan. Regional Cancer Records and Estimated National Figures [in Japanese]
3. Chu E, Cartwright TH (2008) Pharmacoeconomic benefits of capecitabine- based chemotherapy in metastatic colorectal cancer. J Clin Oncol 26: 2224 - 2226; author reply 2228
4. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947
5. Diaz-Rubio E, Tabernero J, Gomez-Espana A, Massuti B, Sastre J, Chaves M, Abad A, Carrato A, Queralt B, Reina JJ, Maurel J, Gonzalez-Flores E, Aparicio J, Rivera F, Losa F, Aranda E (2007) Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 25: 4224-4230
6. Efron B, Tibshirani R (1993) An Introduction to the Bootstrap. Chapman and Hall: New York
7. Garrison L, Cassidy J, Saleh M, Lee F, Mena R, Fuloria J, Chang V, Ervin T, Stella P, Saltz L (2007) Cost comparison of XELOX compared to FOLFOX4 with or without bevacizumab (bev) in metastatic colorectal cancer. J Clin Oncol 25: 182S
8. Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press: New York
9. Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A (2008) The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess 12: iii-iix, xi-162
10. Hochster H, Hart L, Ramanathan R, Hainsworth J, Hedrick E, Childs B (2006) Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE study. J Clin Oncol 24: 148S
11. Jiho (2007) National Health Insurance Drug Price Standard [in Japanese]. Jiho: Tokyo
12. Joint Formulary Committee (2007) British National Formulary 53. British Medical Association and Royal Pharmaceutical Society of Great Britain: London
13. Kelly H, Goldberg RM (2005) Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 23: 4553 - 4560
14. Laboratory SIR (2006) Reimbursement Schedule of Social Insurance and Insurance for the Elderly [in Japanese]. Social Insurance Research Laboratory: Tokyo
15. Lin D, Feuer E, Etzioni R, Wax Y (1997) Estimating medical costs from incomplete follow-up data. Biometrics 53: 419-434
16. Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J (2006) Health state utilities for metastatic breast cancer. Br J Cancer 95: 683 - 690
17. Maroun J, Asche C, Romeyer F, Mukherjee J, Cripps C, Oza A, Skillings J, Letarte J (2003) A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada. Pharmaco-economics 21: 1039-1051
18. Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352: 476 - 487
19. Ministry of Health, Labour and Welfare (2007) Population Survey Report [in Japanese]
20. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274-1281
21. Pandor A, Eggington S, Paisley S, Tappenden P, Sutcliffe P (2006) The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation. Health Technol Assess 10: iii-iiv, xi-xiv, 1 - 185
22. Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ (2007) Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25: 4217-4223
23. Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, Gollins S, Siu LL, Laguerre S, Cunningham D (2008) Capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 19: 1720 - 1726
24. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019
25. Scheithauer W, Cassidy J, Figer A, Wong R, Koski S, Lichinitser M, Yang T, Clarke S, Diaz-Rubio E, Garrison L (2007) A comparison of medical resource use for 4 chemotherapy regimens as first-line treatment for metastatic colorectal cancer (MCRC). J Clin Oncol 25: 4098
26. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45: 291-297
27. Tappenden P, Jones R, Paisley S, Carroll C (2007) Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 11: 1-128, iii-iv
28. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237
29. Twelves C, Gollins S, Grieve R, Samuel L (2006) A randomised cross-over trial comparing patient preference for oral capecitabine and 5 fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 17: 239-245
30. Ward SE, Kaltenthaler E, Cowan J, Marples M, Orr B, Seymour MT (2006) The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer 95: 27-34
31. Willan A, Briggs A (2007) Statistical Analysis of Cost-effectiveness Data. Willy: Chichester